Odyssey Health has announced the creation of a subsidiary called Odyssey Neuropharma that will develop intranasal drugs for the treatment of neurological disorders, including PRV-002 intranasal synthetic neurosteroid for the treatment of concussion. In addition to PRV-002, the company says that it intends to develop spray-dried dry powder nasal formulations for the treatment of Niemann-Pick type C Disease and as an antidote for organophosphate nerve agents.
According to Odyssey, all of the drugs are to be delivered via a breath-powered intranasal delivery device. In October 2021, the company said that it filed a provisional patent application for the device.
Read the Odyssey Health press release.
